LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 21/11/2025 +03			5-day change	1st Jan Change
1.740 ^USD	-3.87%		-.--%	-

11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE

Market Cap	45.77M 40.01M 36.77M 34.28M 65.01M 4.36B 66M 441M 172M 2.14B 172M 168M 7.38B	P/E 2023	-1.01x	P/E 2024	-1.02x
Enterprise Value	-25.52M -22.31M -20.51M -19.11M -36.25M -2.43B -36.8M -246M -95.7M -1.19B -95.81M -93.75M -4.12B	EV / Sales 2023	-7,049,969x	EV / Sales 2024	-3,862,875x
Free-Float	83.62%	Yield 2023 *	-	Yield 2024	-

11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE
11-21	LAVA Therapeutics N.V.(NasdaqGS:LVTX) dropped from NASDAQ Composite Index	CI
11-20	XOMA Royalty Corporation completed the acquisition of LAVA Therapeutics N.V..	CI
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
11-07	LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
17/10/25	XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline	MT
17/10/25	Xoma Royalty and Lava Therapeutics announce amendment to purchase agreement	RE
03/10/25	XOMA Royalty Extends Tender Offer to Acquire Lava Therapeutics	MT
14/08/25	LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/08/25	LAVA Therapeutics N.V. Plans to Discontinue LAVA-1266 Program	CI
05/08/25	Jefferies Downgrades LAVA Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $3	MT
04/08/25	XOMA Royalty Corporation entered a definitive share purchase agreement to acquire LAVA Therapeutics N.V..	CI

11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
05/08/25	Jefferies Downgrades LAVA Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $3	MT
27/02/25	HC Wainwright Downgrades LAVA Therapeutics to Neutral From Buy, Adjusts Price Target to $1.50 From $2	MT
12/12/24	Leerink Partners Downgrades LAVA Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2 From $11	MT
11/12/24	JMP Securities Downgrades LAVA Therapeutics NV to Market Perform From Market Outperform	MT

LAVA Therapeutics Stock

Stocks

LVTX

NL0015000AG6

Biotechnology & Medical Research

Valuation: LAVA Therapeutics

Chart: LAVA Therapeutics

Latest news : LAVA Therapeutics

Analysts' recommendations: LAVA Therapeutics

Press Releases: LAVA Therapeutics

Quotes and Performance

Course Extremes

Managers and Directors: LAVA Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

11-21	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.	AQ
11-13	LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq	AQ
11-11	LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline	AQ
17/10/25	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement	AQ
02/10/25	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.	AQ

1 year	1.3	1.82
3 years	0.85	6.47
5 years	0.85	11.13
10 years	0.85	17.2

Manager	Title	Age	Since
Jessica Truscello CTO	Chief Tech/Sci/R&D Officer	-	09/11/2021
Robin Hume LAW	General Counsel	-	15/05/2023
Wouter van Hunnik HRO	Human Resources Officer	-	09/11/2021

Director	Title	Age	Since
Kapil Dhingra CHM	Chairman	66	22/02/2021
Karen Wilson BRD	Director/Board Member	62	01/03/2021
Owen Hughes BRD	Director/Board Member	51	07/11/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
11-13	Mary Wadlinger	Issuer sale	Director	33,390	0.1269%
11-13	Stephen Hurly	Issuer sale	Chief Executive Officer	340,100	1.2929%
11-13	James Noble	Issuer sale	Director	33,390	0.1269%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVA THERAPEUTICS	-3.87%	-.--%	+31.82%	-9.84%	45.77M
LONZA GROUP AG	+1.70%	+7.41%	+2.50%	+8.18%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+604.02%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.27%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+55.45%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+8.30%	+37.95%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+135.37%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+14.00%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+93.88%	13.52B
Average	+1.57%	+5.24%	+74.15%	+104.20%	24.57B
Weighted average by Cap.	+2.07%	+6.53%	+90.19%	+135.84%

	2023	2024
Net sales	6.77 5.92 5.44 5.07 9.61 644.5 9.76 65.29 25.38 316.81 25.41 24.86 1.09K	11.98 10.47 9.63 8.97 17.02 1.14K 17.28 115.56 44.93 560.79 44.98 44.01 1.93K
Net income	-41.97M -36.69M -33.72M -31.43M -59.62M -4B -60.52M -405M -157M -1.96B -158M -154M -6.77B	-25.11M -21.95M -20.18M -18.81M -35.67M -2.39B -36.21M -242M -94.16M -1.18B -94.27M -92.24M -4.05B
Net Debt	-89.26M -78.03M -71.71M -66.84M -127M -8.5B -129M -861M -335M -4.18B -335M -328M -14.4B	-71.3M -62.33M -57.28M -53.39M -101M -6.79B -103M -688M -267M -3.34B -268M -262M -11.5B